OncoAlert

123.1K posts

OncoAlert banner
OncoAlert

OncoAlert

@OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

Worldwide Katılım Mart 2019
137 Takip Edilen42.1K Takipçiler
Sabitlenmiş Tweet
OncoAlert
OncoAlert@OncoAlert·
Does the Use of PPI affect Immunotherapy?? The @OncoAlert 🚨 newsletter is Out GET IT HERE 👉 buff.ly/JJUzJh1 Stay up to date with the most important practice-changing oncology research, expertly curated with concise take-home messages you can read in minutes. This week's edition features: 🔹 Adjuvant pembrolizumab + belzutifan in high-risk RCC (NEJM) 🔹 Casdatifan in metastatic clear-cell RCC (Nature) 🔹 APCCC Diagnostics 2025 consensus (European Urology) 🔹 PACIFIC analysis on PPIs and immunotherapy (The Lancet Oncology) 🔹 COMPETE trial in GEP-NETs (The Lancet) 🔹 New advances in breast, gynecologic, and hematologic malignancies—and much more. 📩 Join Tens of thousands of oncology professionals worldwide who rely on OncoAlert Weekly newsletter to stay informed with the latest evidence across breast, GI, GU, lung, gynecologic oncology, and hematologic malignancies. Read the latest edition, follow the newsletter, and never miss an update! #OncoAlert #Oncology #CancerResearch #MedTwitter #MedEd #ClinicalTrials #Hematology #BreastCancer #LungCancer #GICancer #GUOncology @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia
English
1
8
20
1.5K
OncoAlert retweetledi
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
Where a cancer starts still matters. But what drives it may matter more. @US_FDA approved selpercatinib for RET fusion-positive advanced solid tumors. @OncoAlert @OpenMedicineHQ
Yüksel Ürün tweet media
English
0
8
23
855
OncoAlert retweetledi
Elvina Almuradova
Elvina Almuradova@Dr_ElvinaA·
FDA approved gedatolisib (Revtorpyk) + fulvestrant ± palbociclib for HR+/HER2−, PIK3CA wild-type advanced/metastatic breast cancer after progression on endocrine therapy. @Larvol @OncoAlert
Elvina Almuradova tweet media
English
0
4
7
363
OncoAlert retweetledi
Petros Grivas
Petros Grivas@PGrivasMDPhD·
@OncoAlert
OncoAlert@OncoAlert

Does the Use of PPI affect Immunotherapy?? The @OncoAlert 🚨 newsletter is Out GET IT HERE 👉 buff.ly/JJUzJh1 Stay up to date with the most important practice-changing oncology research, expertly curated with concise take-home messages you can read in minutes. This week's edition features: 🔹 Adjuvant pembrolizumab + belzutifan in high-risk RCC (NEJM) 🔹 Casdatifan in metastatic clear-cell RCC (Nature) 🔹 APCCC Diagnostics 2025 consensus (European Urology) 🔹 PACIFIC analysis on PPIs and immunotherapy (The Lancet Oncology) 🔹 COMPETE trial in GEP-NETs (The Lancet) 🔹 New advances in breast, gynecologic, and hematologic malignancies—and much more. 📩 Join Tens of thousands of oncology professionals worldwide who rely on OncoAlert Weekly newsletter to stay informed with the latest evidence across breast, GI, GU, lung, gynecologic oncology, and hematologic malignancies. Read the latest edition, follow the newsletter, and never miss an update! #OncoAlert #Oncology #CancerResearch #MedTwitter #MedEd #ClinicalTrials #Hematology #BreastCancer #LungCancer #GICancer #GUOncology @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

QAM
0
3
1
361
OncoAlert retweetledi
Gaia Griguolo
Gaia Griguolo@GaiaGriguolo·
Always good to have an additional treatment option, especially for non-biomarker positive patients!
OncoAlert@OncoAlert

JUST OUT FDA 🇺🇸 approves gedatolisib combined with fulvestrant, with or without palbociclib, for adults with HR-positive, 🧬 HER2-negative, PIK3CA-wild-type locally advanced or metastatic #BreastCancer progressing after endocrine therapy. Approval was based on VIKTORIA-1 fda.gov/drugs/resource… Pinging 🚨Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @amandaNizamMD @DrVilmaPBarcia @DaisukeKotani @DraMartinezLago @DraMartinezLago @UOzkerim @mariobalsamd

English
0
1
2
321
OncoAlert retweetledi
Nieves Martinez Lago MD PhD
Nieves Martinez Lago MD PhD@DraMartinezLago·
🩸 ACT-GI | Phase II 💊 Avatrombopag for persistent CIT in GI cancers ✅ Primary endpoint: 70% vs 17% (P<0.001) 📈 Platelets: 157 vs 72 ×10⁹/L 🚫 No TR serious AEs 🎯 A promising strategy to maintain full-dose, on-schedule chemotherapy. 🔗 doi.org/10.1200/JCO-26… @OncoAlert
Nieves Martinez Lago MD PhD tweet mediaNieves Martinez Lago MD PhD tweet media
English
1
4
4
223
OncoAlert
OncoAlert@OncoAlert·
JUST OUT FDA 🇺🇸 approves gedatolisib combined with fulvestrant, with or without palbociclib, for adults with HR-positive, 🧬 HER2-negative, PIK3CA-wild-type locally advanced or metastatic #BreastCancer progressing after endocrine therapy. Approval was based on VIKTORIA-1 fda.gov/drugs/resource… Pinging 🚨Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @amandaNizamMD @DrVilmaPBarcia @DaisukeKotani @DraMartinezLago @DraMartinezLago @UOzkerim @mariobalsamd
OncoAlert tweet media
English
2
12
18
1.4K
OncoAlert
OncoAlert@OncoAlert·
FDA 🇺🇸granted traditional approval to selpercatinib on July 14, 2026 for adult and pediatric patients (age 2+) with locally advanced or metastatic RET 🧬fusion-positive solid tumors that progressed after prior treatment or lack satisfactory alternatives. fda.gov/drugs/resource… Based on LIBRETTO-001 trial data across non-NSCLC, non-thyroid tumors (n=75), ORR was 47% with median DOR of 24.5 months #LungCancer 🚨 Pinging our Lung Cancer Faculty! @peters_solange @christine_lovly @GlopesMd @DrSanjayPopat @StephenVLiu @HenningWillers @HHorinouchi @BRicciutiMD @PercyLeeMD @jillfeldman4 @bensolomon1 @Latinamd @DrJNaidoo @barlesi @UOzkerim @FernandoOnco @DrMirallas @VanitaNoronha @NarjustFlorezMD @MartinReck2
OncoAlert tweet media
English
0
10
13
1.3K
OncoAlert retweetledi
Nieves Martinez Lago MD PhD
Nieves Martinez Lago MD PhD@DraMartinezLago·
👴 Older CRC patients: who is at highest risk? 📊 Analysis of 777 pts ≥75 y ⚠️ Severe toxicity: 👩 Female 🧠 Cognitive impairment 💊 Doublet ChT 🩸 ⬇️ albumin 🫀 📉 GFR 🎯 Simple clinico-biological models may help personalize treatment decisions. 🔗 doi.org/10.1016/j.ejca… @OncoAlert
Nieves Martinez Lago MD PhD tweet media
English
0
4
9
847
OncoAlert retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🚨 A new biomarker-driven standard in thyroid cancer? Phase III trial in previously treated BRAF V600E-positive, RAI-refractory differentiated thyroid cancer: Dabrafenib + trametinib vs placebo ✅ PFS: 12.8 vs 3.7 months HR 0.38, p<0.0001 ✅ ORR: 57% vs 4% ⚠️ Interim OS: HR 0.66, not significant Pyrexia: 48% Serious AEs: 43% vs 25% Take-home: A major PFS and response benefit after VEGFR-targeted therapy. Verdict: Practice Changing Would you choose this over cabozantinib? @TheLancetOncol @oncoalert #ThyroidCancer #PrecisionOncology
Dr Rishabh Jain tweet media
English
0
8
20
1.6K
OncoAlert retweetledi
Luca Arecco, MD
Luca Arecco, MD@Lucarecco·
One size does not fit all! Just published in @JNCI_Now a M-A suggesting that TROP2 expression may help identify pts deriving the greatest benefit from TROP2-ADCs, reinforcing the need for predictive biomarkers to optimize pts selection! Thank you and congrats @RobertoBuonaiu3 @MicheleDelauren @CarmineDeA1 👏🏼👏🏼👏🏼 @OncoAlert
Luca Arecco, MD tweet mediaLuca Arecco, MD tweet media
English
3
9
22
2K
OncoAlert retweetledi
Mario Balsa
Mario Balsa@MarioBalsaMD·
⏰ Does the timing of anti–PD-1 infusions matter? (NCI/SWOG S1404, n=628) ascopubs.org/doi/full/10.12… ☝🏼 No association between earlier infusion time and RFS or OS after bias-adjusted analyses 💥 Time-dependent multivariable models failed to confirm any survival benefit 🚗 Distance to the treatment center influenced infusion timing, highlighting an important confounder Maybe the clock wasn’t ticking in favor of IO…just in favor of bias! @OncoAlert @OncoReporte @_SEOM @myESMO
Mario Balsa tweet mediaMario Balsa tweet media
English
0
18
43
24.3K
OncoAlert retweetledi
IJGC
IJGC@IJGConline·
🩺 Can #ultrasound reliably detect #residual #cervical cancer after #conization? 📍#URECA Study (n=166): ✅ Sensitivity: 74.7% ❗Specificity: 52.7% 📊 Accuracy: 62.7% Residual disease remains challenging to identify, emphasizing the importance of better imaging strategies and optimal timing after conization. 🔗 bit.ly/4wz1P9H @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc
IJGC tweet media
English
0
6
10
784
OncoAlert retweetledi
ASCO
ASCO@ASCO·
Drs. @KelseyNatsuhara, @QuantumOnc, and Paramveer Singh reflect on their experiences as early-career oncologists across three distinct practice settings—community, academic, and international—and offer practical insights for trainees. Read more: bit.ly/4vydCnX
ASCO tweet media
English
0
5
18
2.1K
OncoAlert retweetledi
Mario Balsa
Mario Balsa@MarioBalsaMD·
🚨 Every week, the oncology literature grows. So does the need for trusted expert curation! Another outstanding edition of the @OncoAlert Newsletter covering the science that matters most 🔗 oncoalert.m-pages.com/nhMpwe/oncoale…
OncoAlert@OncoAlert

📢 The OncoAlert Newsletter | This Week's Edition Is Out 🔥July 2-9 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf ⭐ SPOTLIGHT TRIAL: Adjuvant Pembrolizumab + Belzutifan for Renal-Cell Carcinoma — does adding a HIF-2α inhibitor to adjuvant immunotherapy change the game for high-risk resected ccRCC? The phase 3 data are in, and the efficacy-toxicity trade-off is worth a close look. Also in this edition: 🧬 Casdatifan's durable HIF-2α-driven response in refractory metastatic RCC 🩺 APCCC 2025: consensus reached on just 19% of prostate cancer diagnostic questions 🫁 Do PPIs blunt durvalumab's efficacy after chemoradiotherapy in stage III NSCLC? 🎯 [177Lu]Lu-edotreotide outperforming everolimus in GEP-NETs (COMPETE trial) 🎗️ Trastuzumab rezetecan nearly quadruples PFS in HER2+ metastatic breast cancer ➕ 4 more studies spanning lung, GI, breast, gyn onc, and multiple myeloma Curated for oncology professionals, by oncology professionals. Read the full edition 👉 OncoAlert360.com #OncologyNews #RenalCellCarcinoma #KidneyCancer #NSCLC #BreastCancer #NeuroendocrineTumors #MultipleMyeloma #Oncology #ClinicalResearch #OncoAlert @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

English
0
3
7
907

Keşfet

@US_FDA @OpenMedicineHQ @Larvol @lcsmchat @OncLive @Onco_Nexus @OncogeneCancer @LungCancerRx